

ANASTASIS BIOTEC LIMITED

**Company Registration Number:
10502511 (England and Wales)**

Unaudited abridged accounts for the year ended 31 December 2018

Period of accounts

Start date: 01 January 2018

End date: 31 December 2018

ANASTASIS BIOTEC LIMITED

Contents of the Financial Statements for the Period Ended 31 December 2018

Balance sheet

Notes

ANASTASIS BIOTEC LIMITED

Balance sheet

As at 31 December 2018

	<i>Notes</i>	<i>2018</i>	<i>13 months to 31 December 2017</i>
		<i>£</i>	<i>£</i>
Fixed assets			
Intangible assets:	3	35,482	9,600
Total fixed assets:		<u>35,482</u>	<u>9,600</u>
Current assets			
Debtors:	4	4,272	970
Cash at bank and in hand:		4,314	11,287
Total current assets:		<u>8,586</u>	<u>12,257</u>
Creditors: amounts falling due within one year:	5	(36,187)	(12,045)
Net current assets (liabilities):		<u>(27,601)</u>	<u>212</u>
Total assets less current liabilities:		<u>7,881</u>	<u>9,812</u>
Total net assets (liabilities):		<u>7,881</u>	<u>9,812</u>
Capital and reserves			
Called up share capital:		31,146	21,500
Profit and loss account:		(23,265)	(11,688)
Shareholders funds:		<u>7,881</u>	<u>9,812</u>

The notes form part of these financial statements

ANASTASIS BIOTEC LIMITED

Balance sheet statements

For the year ending 31 December 2018 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company's profit & loss account.

**This report was approved by the board of directors on 01 September 2019
and signed on behalf of the board by:**

Name: Prof Agamemnon Epenetos
Status: Director

The notes form part of these financial statements

ANASTASIS BIOTEC LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2018

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

ANASTASIS BIOTEC LIMITED

Notes to the Financial Statements for the Period Ended 31 December 2018

2. Employees

	<i>2018</i>	<i>13 months to 31 December 2017</i>
Average number of employees during the period	0	0

ANASTASIS BIOTEC LIMITED

Notes to the Financial Statements for the Period Ended 31 December 2018

3. Intangible Assets

	Total
Cost	£
At 01 January 2018	10,000
Additions	30,536
At 31 December 2018	<u>40,536</u>
Amortisation	
At 01 January 2018	400
Charge for year	4,654
At 31 December 2018	<u>5,054</u>
Net book value	
At 31 December 2018	<u>35,482</u>
At 31 December 2017	<u>9,600</u>

ANASTASIS BIOTEC LIMITED

Notes to the Financial Statements for the Period Ended 31 December 2018

4. Debtors

	<i>2018</i>	<i>13 months to 31 December 2017</i>
	<i>£</i>	<i>£</i>
Debtors due after more than one year:	0	0

ANASTASIS BIOTEC LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2018

5. Creditors: amounts falling due within one year note

2018	2017	Trade creditors	27,542	-	Other creditors	7,195	10,845	Accruals and deferred income	1,450	1,200
------	------	-----------------	--------	---	-----------------	-------	--------	------------------------------	-------	-------

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.